Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Kirk Pharmaceuticals, LLC
WARNING LETTER
•Kirk Pharmaceuticals, LLC•July 2, 2009

Kirk Pharmaceuticals, LLC – FDA Warning Letter, Jul 2, 2009

Record Details

This Warning Letter, issued by the FDA to Kirk Pharmaceuticals, LLC on February 4, 2010, details significant Current Good Manufacturing Practice (CGMP) violations observed during a June 17-July 2, 2009 inspection. These violations render the firm's drug products adulterated.

Key violations include: 1. **Failure to reject out-of-specification (OOS) drug products:** Isoxsuprine Hydrochloride 20 mg tablets, lot (b)(4), with an OOS assay result, were released for distribution. The firm's investigation was deemed inadequate. 2. **Inadequate investigation of failures:** * Failure to investigate dissolution failures for Ephedrine Hydrochloride 12.5 mg/Guaifenesin 200 mg hard gelatin capsules validation lots. * Untimely investigation of blend uniformity failures for Diphenhydramine Hydrochloride 25 mg blend lots (b)(4) and (b)(4). * Inadequate investigations of dissolution failures for Diphenhydramine Hydrochloride 25 mg capsules at accelerated stability conditions, and discontinuation of studies without justification. * Failure to extend an investigation of an assay failure for Diphenhydramine Hydrochloride 25 mg capsules, lot (b)(4), to all distributed sub-lots. This is a repeat observation. 3. **Unvalidated test methods:** The

Company
Kirk Pharmaceuticals, LLC
Inspection date
July 2, 2009
Product type
Drugs
Office
Florida District Office
People
  • Emma R. Singleton (District Director)
  • Winston R. Alejo (Student at University of North Carolina at Greensboro)
View Company Profile

ID · 6ed74e75-c426-455c-bff5-ba882c6dd53f

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.165(f)21 CFR 211.19221 CFR 211.165(e)21 CFR 211.110(b)21 CFR 211.22(d)21 CFR 211.180(e)FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Kirk Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.